Table 2. Treatment response with targeted agents in IPW-adjusted cohort.
| Treatment response | pNEN (%) | epNEN (%) | |||||
|---|---|---|---|---|---|---|---|
| Suru | Suni + Eve | P value | Suru | Eve | P value | ||
| Best response | <0.001 | ||||||
| PR | 21.0 | 9.9 | 0.004 | 6.2 | 5.6 | ||
| SD | 70.2 | 65.7 | 79.7 | 58.4 | |||
| PD | 8.8 | 24.3 | 14.1 | 36.0 | |||
| ORR | 21.0 | 9.9 | 0.03 | 6.2 | 5.6 | 0.84 | |
| DCR | 91.2 | 75.7 | 0.004 | 85.9 | 64.0 | <0.001 | |
IPW, inverse probability weighting; pNEN, pancreatic neuroendocrine neoplasm; epNEN, extrapancreatic neuroendocrine neoplasm; Suru, surufatinib; Suni, sunitinib; Eve, everolimus; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.